Cite
Miltiades P, Lamprianidou E, Vassilakopoulos TP, et al. Expression of CD25 antigen on CD34+ cells is an independent predictor of outcome in late-stage MDS patients treated with azacitidine. Blood Cancer J. 2014;4:e187doi: 10.1038/bcj.2014.9.
Miltiades, P., Lamprianidou, E., Vassilakopoulos, T. P., Papageorgiou, S. G., Galanopoulos, A. G., Vakalopoulou, S., Garypidou, V., Papaioannou, M., Hadjiharissi, E., Pappa, V., Papadaki, H. A., Spanoudakis, E., Tsatalas, K., & Kotsianidis, I. (2014). Expression of CD25 antigen on CD34+ cells is an independent predictor of outcome in late-stage MDS patients treated with azacitidine. Blood cancer journal, 4e187. https://doi.org/10.1038/bcj.2014.9
Miltiades, P, et al. "Expression of CD25 antigen on CD34+ cells is an independent predictor of outcome in late-stage MDS patients treated with azacitidine." Blood cancer journal vol. 4 (2014): e187. doi: https://doi.org/10.1038/bcj.2014.9
Miltiades P, Lamprianidou E, Vassilakopoulos TP, Papageorgiou SG, Galanopoulos AG, Vakalopoulou S, Garypidou V, Papaioannou M, Hadjiharissi E, Pappa V, Papadaki HA, Spanoudakis E, Tsatalas K, Kotsianidis I. Expression of CD25 antigen on CD34+ cells is an independent predictor of outcome in late-stage MDS patients treated with azacitidine. Blood Cancer J. 2014 Feb 28;4:e187. doi: 10.1038/bcj.2014.9. PMID: 24583533; PMCID: PMC3944665.
Copy
Download .nbib